Therapygenetics: 5-HTTLPR genotype predicts the response to exposure therapy for agoraphobia

Eur Neuropsychopharmacol. 2014 Aug;24(8):1222-8. doi: 10.1016/j.euroneuro.2014.05.007. Epub 2014 May 20.

Abstract

This study was intended to assess the extent to which the low-expression allele of the serotonin transporter gene promoter predicts better response to exposure-based behavior therapy in patients with panic disorder with agoraphobia (PDA). Ninety-nine patients with PDA underwent a 1-week in vivo exposure-based behavior therapy program and provided saliva samples to extract genomic DNA and classify individuals according to four allelic forms (SA, SG, LA, LG) of the 5-HTT-linked polymorphic region (5-HTTLPR). We determined whether the 5-HTTLPR genotype predicted change in avoidance behavior in PDA following treatment. After controlling for pre-treatment avoidance behavior, the 5-HTTLPR low-expression genotypes showed a more favorable response to exposure therapy two weeks following treatment, compared to the other patients. This study suggests a genetic contribution to treatment outcome following behavior therapy and implicates the serotonergic system in response to exposure-based treatments in PDA.

Keywords: Agoraphobia; Behavior therapy; Exposure therapy; Genetics; Panic disorder; Serotonin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Agoraphobia / complications
  • Agoraphobia / genetics*
  • Agoraphobia / rehabilitation*
  • Analysis of Variance
  • Female
  • Gene Frequency
  • Genetic Testing
  • Genotype
  • Humans
  • Implosive Therapy / methods*
  • Male
  • Middle Aged
  • Polymorphism, Genetic / genetics*
  • Promoter Regions, Genetic / genetics
  • Psychiatric Status Rating Scales
  • Serotonin Plasma Membrane Transport Proteins / genetics*
  • Somatoform Disorders / complications
  • Treatment Outcome

Substances

  • SLC6A4 protein, human
  • Serotonin Plasma Membrane Transport Proteins